Tirofiban administration and percutaneous coronary intervention with stenting of saphenous vein graft thrombosis

Journal of Cardiovascular Medicine

Volumn 10, Issue 11, 2009, Pages 875-878

  D'Andrea, Claudia ^a   Esposito, Giovanni ^a   Piscione, Federico ^a,b   Chiariello, Massimo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Department of Clinical Medicine Cardiovascular Sciences and Immunology ^*  (Italy)

Author keywords

Percutaneous coronary intervention; Saphenous vein graft; Tirofiban

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOT LYSIS; CARDIAC PATIENT; CORONARY ARTERY BLOOD FLOW; CORONARY STENT; DRUG ELUTING STENT; LEFT ANTERIOR DESCENDING CORONARY ARTERY; PERCUTANEOUS CORONARY INTERVENTION; SAPHENOUS VEIN GRAFT THROMBOSIS; THERAPY EFFECT; TREATMENT RESPONSE; VEIN GRAFT DISEASE; VEIN OCCLUSION; VEIN THROMBOSIS;

AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CONSTRICTION, PATHOLOGIC; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; DRUG ADMINISTRATION SCHEDULE; EMBOLISM; FIBRINOLYTIC AGENTS; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; SAPHENOUS VEIN; STENTS; THROMBOSIS; TREATMENT OUTCOME; TYROSINE;

EID: 70349843626     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32832e669a     Document Type: Article

References (19)

1. Mehta RH, Honeycutt E, Shaw LK,Glower D, Harrington RA, Sketch MH Jr. Clinical correlates of long-termmortality after percutaneous interventions of saphenous vein grafts. Am Heart J 2006; 152:801-806.
2. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996; 28:616-626.
3. de Feyter PJ, van Suylen RJ, de Jaegere PP, Topol EJ, Serruys PW. Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts. J Am Coll Cardiol 1993; 21:1539-1549.
4. Weintraub WS, Jones EL, Craver JM, Guyton RA. Frequency of repeat coronary bypass or coronary angioplasty after coronary artery bypass surgery using saphenous venous grafts. Am J Cardiol 1994; 73:103-112.
5. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol 2007; 50:2173-2195. (Pubitemid 350123680)
6. Guthaner DF, Robert EW, Alderman EL, Wexler L. Long-term serial angiographic studies after coronary artery bypass surgery. Circulation 1979; 60:250-259.
7. Foster ED, Fisher LD, Kaiser GC, Myers WO. Comparison of operative mortality and morbidity for initial and repeat coronary artery bypass grafting: the Coronary Artery Surgery Study (CASS) registry experience. Ann Thorac Surg 1984; 38:563-570.
8. Seides SF, Borer JS, Kent KM, Rosing DR, McIntosh CL, Epstein SE. Longterm anatomic fate of coronary-artery bypass grafts and functional status of patients five years after operation. N Engl J Med 1978; 298:1213-1217.
9. Grondin CM, Campeau L, Lesperance J, Enjalbert M, Bourassa MG. Comparison of late changes in internal mammary artery and saphenous vein grafts in two consecutive series of patients 10 years after operation. Circulation 1984; 70 (3 Pt 2):I208-I212.
10. Lefkovits J, Holmes DR, Califf RM, Safian RD, Pieper K, Keeler G, et al. Predictors and sequelae of distal embolization during saphenous vein graft intervention from the CAVEAT-II trial. Coronary Angioplasty Versus Excisional Atherectomy Trial. Circulation 1995; 92:734-740.
11. Kalyanasundaram A, Blankenship JC, Berger P, Herrmann H, McClure R, Moliterno D. Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?). Catheter Cardiovasc Interv 2007; 69:623-629.
12. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344:1888-1894.
13. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330:956-961.
14. Servoss SJ, Wan Y, Snapinn SM, DiBattiste PM, Zhao XQ, Theroux P, et al. Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial. Am J Cardiol 2004; 93:843-847.
15. Kurowski V, Toelg R, Jain D, Richter C, Wiegand UK, Richardt G, et al. Effect of adjunctive treatment with tirofiban on troponin T elevation during stenting of critically stenosed aortocoronary saphenous vein grafts. Am J Cardiol 2005; 96:681-684.
16. Roffi M, Mukherjee D, Chew DP, Bhatt DL, Cho L, Robbins MA, et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation 2002; 106:3063-3067.
17. Mathew V, Grill DE, Scott CG, Grantham JA, Ting HH, Garratt KN, et al. The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions. J Am Coll Cardiol 1999; 34:1163-1169.
18. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Catheter Cardiovasc Interv 2008; 71:E1-E40.
19. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (ACC/ AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113:e166-e286.